

AHNS Series: Do you know your guidelines? Optimizing outcomes in reoperative parathyroid surgery: Definitive multidisciplinary joint consensus guidelines of the American Head and Neck Society and the British Association of Endocrine and Thyroid Surgeons

Brendan C. Stack Jr MD^{1*} | **Neil S. Tolley MD, DLO^{2*}** |
Twyla B. Bartel DO, MBA³ | **John P. Bilezikian MD⁴** | **Donald Bodenner MD, PhD⁵** |
Pauline Camacho MD⁶ | **Jeremy P. D. T. Cox MBBS, MD, FRCP⁷** |
Henning Dralle MD⁸ | **James E. Jackson FRCP, FRCR⁷** | **John C. Morris III MD¹⁰** |
Lisa Ann Orloff MD¹¹ | **Fausto Palazzo MS, FRCS²** | **John A. Ridge MD, PhD¹²** |
David Scott-Coombes FRCS¹³ | **David L. Steward MD¹⁴** | **David J. Terris MD¹⁵** |
Geoffrey Thompson MD¹⁶ | **Gregory W. Randolph MD¹⁷**

¹Department of Otolaryngology - Head and Neck Surgery, University of Arkansas for Medical Sciences, Little Rock, Arkansas

²Hammersmith Hospital, Imperial College NHS Healthcare Trust, London, UK

³Global Advanced Imaging, PLLC, Little Rock, Arkansas

⁴Department of Medicine, Division of Endocrinology, Columbia University College of Physicians and Surgeons, New York, New York

⁵Department of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas

⁶Department of Medicine, Division of Endocrinology, Loyola University, Chicago, Illinois

⁷Department of Metabolic Medicine, Imperial College Hospital, NHS Healthcare Trust, London, UK

⁸Sektion Endokrine Chirurgie, Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Medizinisches Zentrum, Germany

⁹Department of Imaging, Hammersmith Hospital, Imperial College NHS Healthcare Trust, London, UK

¹⁰Department of Medicine, Division of Endocrinology, Mayo Clinic, Rochester, Minnesota

¹¹Department of Otolaryngology - Head and Neck Surgery, Stanford University, Palo Alto, California

¹²Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania

¹³Department of Surgery, Cardiff and Vale Hospitals, Wales, UK

¹⁴Department of Otolaryngology - Head and Neck Surgery, University of Cincinnati, Cincinnati, Ohio

¹⁵Department of Otolaryngology - Head and Neck Surgery, Augusta University, Augusta, Georgia

¹⁶Department of Surgery, Mayo Clinic, Rochester, Minnesota

¹⁷Department of Otolaryngology - Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Harvard University, Boston, Massachusetts

*Brendan C. Stack Jr and Neil S. Tolley contributed equally to this study.

Correspondence

Brendan Stack, Department of
Otolaryngology - Head and Neck
Surgery, University of Arkansas for
Medical Sciences, 4301 W. Markham,
Slot #543, Little Rock, AR 72205.,
Email: bstack@uams.edu

Abstract

Background: Revision parathyroid is challenging due to possible diagnostic uncertainty as well as the technical challenges it can present.

Methods: A multidisciplinary panel of distinguished experts from the American Head and Neck Society (AHNS) Endocrine Section, the British Association of Endocrine and Thyroid Surgeons (BAETS), and other invited experts have reviewed this topic with the purpose of making recommendations based on current best evidence. The literature was also reviewed on May 12, 2017. PubMed (1946-2017), Cochrane SR (2005-2017), CT databases (1997-2017), and Web of Science (1945-2017) were searched with the following strategy: revision and reoperative parathyroidectomy to ensure completeness.

Results: Guideline recommendations were made in 3 domains: preoperative evaluation, surgical management, and alternatives to surgery. Eleven guideline recommendations are proposed.

Conclusion: Reoperative parathyroid surgery is best avoided if possible. Our literature search and subsequent recommendations found that these cases are best managed by experienced surgeons using precision preoperative localization, intraoperative parathyroid hormone (PTH), and the team approach.

KEYWORDS

consensus, guidelines, parathyroid, reoperative, surgery

1 | INTRODUCTION

We reviewed the evaluation and management of patients undergoing reoperative surgery for primary hyperparathyroidism (HPT). A multidisciplinary panel of distinguished experts from the American Head and Neck Society (AHNS) Endocrine Section, the British Association of Endocrine and Thyroid Surgeons (BAETS), and other invited experts have reviewed this topic with the purpose of making recommendations based on current best evidence. This endeavor included 8 current or past presidents of the American Thyroid Association (ATA), American Association of Clinical Endocrinologists, American Academy of Otolaryngology Head and Neck Surgery (AAO-HNS), International Association of Endocrine Surgeons, British Association of Endocrine and Thyroid Surgeons (BAETS), American Association of Endocrine Surgeons, European Society of Endocrine Surgeons, and the AHNS. Consensus recommendations for the diagnosis and management of reoperative procedures for patients with hyperparathyroidism are presented.

Reoperative parathyroid surgery can be associated with significant risks. It may be required in as many as 10% of operated patients with primary hyperparathyroidism.¹ Reoperative parathyroid surgery is a complex exercise that requires specialized skills and understanding to successfully optimize patient care. We offer this statement of consensus guidelines in a spirit of interspecialty and international

collaboration to improve the care of patients with persistent and recurrent hyperparathyroidism after previous surgery. We feel the blend of expertise of our author panel substantially strengthens the work and ultimately our recommendations. We recognize that some of the recommendations are made with an overarching general/universal purpose and that local parochial issues (such as, for example, what form of imaging may be available) will vary by region and individual center.

This consensus statement from the AHNS and BAETS focuses on comprehensive management. The document includes preoperative diagnostic and intraoperative anatomic surgical maneuvers and technical information. The recommendations of the AHNS, the largest surgical organization in the United States, focused on thyroid cancer treatment, as well as the BAETS, the United Kingdom's endocrine surgical organization, are intended to help guide surgeons in the clinical decision-making process when managing patients requiring reoperative parathyroid surgery. It is our hope that this document improves the quality and reduces variation in management of such patients and facilitates further communication and research for these patients who require parathyroid surgical procedures.

Evidence-based support is drawn from the literature, authors' expert opinion, as well as recent existing AAO-HNS, AHNS, and ATA guidelines. The literature was also reviewed on May 12, 2017, (PubMed 1946-2017; Cochrane

SR 2005-2017; CT databases 1997-2017; and Web of Science 1945-2017) and were searched with the following strategy: revision and reoperative parathyroidectomy to ensure completeness. References were classified by the Oxford Centre for Evidence-Based Medicine System.² The manuscript was generated by members of the author panel and then distributed to governing counsels of both organizations for further iterative feedback and ultimate organizational approval.

2 | SECTION 1: PREOPERATIVE EVALUATION

2.1 | Recommendation 1a

The first step in the evaluation of the reoperative procedures for patients with hyperparathyroidism must include complete biochemical confirmation of primary HPT with hypercalcemia, relative or absolute hyperparathormonemia, and preferably hypercalciuria before reoperation. Level of evidence: 1 to 3, level of recommendation: strong.

The biochemical diagnosis of persistent and recurrent primary hyperparathyroidism is the same as for the initial diagnosis of primary HPT, specifically, hypercalcemia in the presence of a high or inappropriately unsuppressed parathyroid hormone (PTH) level.^{1,3,4}

Persistent HPT is defined as hypercalcemia within 6 months of the initial parathyroidectomy, whereas recurrent HPT is defined as hypercalcemia occurring 6 months or more after parathyroidectomy. Persistent HPT is typically due to inadequate surgery, whereas recurrent HPT is usually due to a lack of appreciation for the underlying disease process (either sporadic or genetic; eg, multiple endocrine neoplasia type-1)^{5,6} Recurrent HPT in multiple endocrine neoplasia type-1 is an expected outcome after adequate primary initially successful surgery. Patients with recurrent HPT are more likely to have a family history of hyperparathyroidism and/or have had their initial parathyroid surgery performed earlier in life.

Patients who have had parathyroid surgery have typically met one or more of the generally accepted guidelines for surgery. In these patients, indications for surgery have not changed except for the fact that they have had unsuccessful parathyroid surgery and now have new increased risks associated with the reoperative procedure. In those patients who underwent parathyroid surgery, but did not meet any specific guidelines, the decision to consider another parathyroid operation is not straightforward. Asymptomatic patients with primary hyperparathyroidism have been followed for up to a decade without overt evidence of clinically significant disease progression.¹

The threshold for reoperative surgery should be higher than for first time surgery; therefore, a quantitative

assessment of disease severity is required. Basic assessment of the degree of hypercalcemia (such as a serum calcium >3.00 mmol/L [12.0 mg/dL]) may be complemented by evaluation of kidney function (especially the glomerular filtration rate), renal imaging (abdominal ultrasound or CT for nephrolithiasis/nephrocalcinosis), somatic symptoms (musculoskeletal aches and pains), assessment of bone health (with dual-energy X-ray absorptiometry), and an assessment of cardiovascular risk. Ultimately, thorough and more aggressive imaging than for the initial operation is the basis of successful parathyroid reoperation.^{7,8}

The overarching cost-benefit analysis of reoperative parathyroid surgery blends the stable issues of disease risk/morbidity and the now increased surgical risk of the more difficult scarred surgical field. The decision to move forward with surgery must be nuanced and shared with the patient and their endocrinologist.

2.2 | Recommendation 1b

The diagnosis of HPT must be secured through exclusion of nonparathyroid causes of hypercalcemia and/or hyperparathormonemia. Level of evidence: 2C, level of recommendation: moderate.

Several factors may influence biochemical results and lead to confusion in patient assessment. Vitamin D deficiency and calcium deficiency, particularly if severe, may mask primary HPT, as such patients may present with a normal calcium level. In addition, the 24-hour urine calcium excretion may be low in severely calcium-deficient individuals and the biochemical picture can even mimic secondary hyperparathyroidism. Correction of any documented deficiencies and repeat testing after replacement therapy may reveal the true diagnosis of primary HPT. It must be noted that patients who are vitamin D deficient and are hypercalcemic at the outset should be repleted cautiously; otherwise the hypercalcemia can be exacerbated.

The use of thiazide diuretics and lithium, which may raise PTH and cause mild hypercalcemia, may mimic the diagnosis of primary HPT. These medications should be discontinued when possible and the biochemical evaluation repeated after 6 weeks. Nonparathyroid-mediated hypercalcemia (ie, lymphoma, granulomatous diseases, hyperthyroidism, metastatic bone disease, multiple myeloma, vitamin D toxicity, and milk-alkali syndrome) are distinguished from primary HPT by an appropriately suppressed PTH paired with the elevated calcium. The PTH-related peptide can be assayed when PTH is suppressed in the presence of hypercalcemia. Familial hypocalciuric hypercalcemia must be excluded with a 24-hour urine collection and estimation of the calcium: creatinine clearance ratio. This can be done based on low urinary calcium: creatinine excretion ratio of <0.01. If below 0.01, a mutational analysis of the calcium-

sensing receptor and possibly G alpha 11 and AP2S1 may be pursued. Conversely, a renal leak of calcium (hypercalciuria) can result in a compensatory raise in PTH and would cause persistent hyperparathyronemia even after successful surgery for hyperparathyroidism.⁹

2.3 | Recommendation 2

Detailed review of past surgical and pathologic data is essential to optimize surgical success. Level of evidence: 3A-B, level of recommendation: strong.

When a patient is referred for consideration of further parathyroid surgery, it is essential that the multidisciplinary team gathers key patient data. The increased risk of a second exploration through a scarred field requires additional scrutiny to be certain of the diagnosis and to decide whether additional surgery is justified.¹⁰ The prior operative notes and pathology reports typically provide important information (although some interpretation may be required), and should be retrieved along with the imaging reports and images obtained before the original operation. This data can be transferred to a surgical planning worksheet (see Figure 1).

Once a decision to operate has been made, the likelihood of single or multiple gland pathology and the likely location of the (missed) lesion(s) need to be determined. If none or only normal parathyroid gland(s) were excised at the first operation, it is likely that the patient still retains a solitary adenoma.¹¹ Therefore, a forensic analysis of the operation notes, the pathology report, and biochemistry results both intraoperatively and perioperatively is fundamental. Particular attention should be paid to which glands were identified, which were removed, and what the pathology was on each excised specimen. From this one might derive the most likely site (quadrant) for the lesion, increase the likelihood of success, and reduce the likelihood of hypoparathyroidism that might result from revision exploration. This analysis also anticipates where scarring is most likely to be encountered.^{12,13} The possibility of parathyromatosis should also be considered if there was any suggestion of capsule rupture during the previous surgery. It should be possible to establish from the pathology and imaging reports whether the tissue removed was parathyroid and ascertain its weight and histological characteristics.

2.3.1 | Common anatomic explanations for surgical failure

As a matter of definition, persistent or recurrent hyperparathyroidism requiring reoperation means that the patient must harbor one or more hyperfunctioning parathyroid glands. These may be situated within the central compartment in “normal” or “near normal” locations or they may be in ectopic positions. Knowledge of the normal anatomic




FIGURE 1 Technique for “forensic” localization of likely adenoma based on previous pathology and operative reports. Information can be recoded like above A, to focus the surgeon’s interest to a particular quadrant of interest in the reoperative neck B. Thyroid biopsy should be judiciously used. This figure was republished with permission from Andrew M. Hinson, MD [Color figure can be viewed at wileyonlinelibrary.com]

positions, known embryological variants, and parathyroid migration patterns is requisite in the preoperative planning.

Failed parathyroid operations often have identifiable anatomic or technical reasons (ie, a low lying superior gland). Missed adenomas are usually in “normal” positions, although their size over time may promote additional descent into the central neck compartment.¹⁴ A large superior gland will often sink into a paraesophageal location posterior to the recurrent laryngeal nerve. Surgeon reluctance at the initial operation to manipulate the nerve is a common cause of failure to identify such an adenoma. A missed lower gland is often associated with an undescended thymus, and missed upper glands are more typically retroesophageal or retropharyngeal.¹⁵ The clinical statement is true: “if you are looking for a missed upper gland look low, if looking for a missed lower gland look high.”

The true incidence of ectopic and supernumerary glands in the neck is on the order of 1% with autopsy series suggesting a higher frequency than encountered clinically.¹⁶ Failure to identify glands in characteristic anatomic position(s) is a more common occurrence than the presence of a supernumerary gland. True intrathyroidal parathyroids are also rare; they are more commonly closely attached to nodular thyroid gland capsule than truly intrathyroidal.¹⁷ An unappreciated intrathoracic gland may be within the thymus, the posterior mediastinum, or the aortopulmonary window.¹⁸ Unless heralded by imaging, ectopic gland detection before the first reexploration is uncommon because most primary operations focus upon suspected abnormal glands within the neck.

Unappreciated multiple gland disease (whether from a “double adenoma” or “hyperplasia”) constitutes a different

problem from frank failure to localize the offending adenoma at the initial operation. Unsuccessful control of 4-gland disease, present in some 10% of patients, is not typically associated with difficulty in locating the glands, but rather with misinterpreting the character of abnormal glands found in usual locations. If the original surgeon used intraoperative PTH, they may have been misled by a reassuring drop in PTH when an insufficient parathyroidectomy had been performed. In such cases, more extensive parathyroid resection combined with a plan for cryopreservation and autotransplantation may have been indicated.

2.4 | Recommendation 3

Assessment of the patient's current health status and previous surgical complications, if any, must be made before planning for reoperative surgery. Level of evidence: 1-3, level of recommendation: moderate.

Key factors to be considered include known anesthetic risk(s), technical difficulty of additional surgery in a scarred area, and previous complications, such as vocal cord palsy. Finally, these factors need to be brought to bear on the decision on whether the degree of hyperparathyroidism merits reoperation at the present time.^{19,20}

One must be mindful of interim events that may have occurred that place the patient at greater risk. There may have been progression of existing medical comorbidities from the time of the first procedure. Additional medical conditions may have developed. The persistent or recurrent hyperparathyroidism may have exacerbated or accelerated end organ damage.

2.5 | Recommendation 4

Preoperative laryngeal assessment is required in all patients before reoperative parathyroid surgery. Level of evidence: 3A, level of recommendation: strong.

It is imperative to assess the reoperative patient for laryngeal complications that might have occurred as a result of the first parathyroidectomy procedure. These may or may not be heralded by a reported change in voice. Both the Scandinavian Endocrine Registry and the British Endocrine Audit data suggest rates of vocal cord paralysis increase if patients are examined routinely as opposed to only if symptomatic; typically, these rates double.²¹⁻²³ It is essential in all patients that vocal cord assessment by flexible laryngoscopy be performed as part of their initial evaluation. If there is a vocal cord weakness, this presents a major challenge. If reexploration is confined to the paralyzed or paretic side, perhaps the patient would be exposed to little or no additional risk of ill effects upon their voice from the reoperative procedure. If, however, surgery is conducted on the contralateral side, the only remaining mobile cord is placed at risk. The patient is

now at an increased risk for a postoperative bilateral vocal cord paresis that could require a tracheotomy. This possibility must be clearly discussed with the patient with full and written informed consent obtained, which significantly impacts on the core decision making for reoperative surgery.²⁴ The mandatory nature of the laryngeal examination is denoted in multiple major recent endocrine multidisciplinary guidelines, including the AAO-HNS, the ATA guidelines, and the AHNS guidelines.^{23,25,26}

2.6 | Recommendation 5a

Preoperative imaging of reoperative parathyroid surgical patients is mandatory. Level of evidence: 1-3, level of recommendation: strong.

The importance of obtaining any imaging undertaken before first-time surgery for review cannot be understated. It is common that review by a radiologist experienced in parathyroid imaging will identify a likely location of the disease.³ Thus, localization of the target parathyroid lesion is essential before proceeding with reoperative parathyroid surgery.

2.7 | Recommendation 5b

Using the imaging modality that is readily available, most reliable, and cost-effective in a given health system is recommended. This will vary depending on location. Level of evidence: 1-3, level of recommendation: moderate.

2.7.1 | Ultrasound

After previous parathyroid surgery, a patient with persistent or recurrent hyperparathyroidism should undergo ultrasonography of the neck as the first-line imaging study. Ultrasound is highly operator-dependent, and a candidate parathyroid adenoma may be recognized where it was missed by a prior sonographer. Surgeon-performed ultrasound have been shown to be at least as successful as radiologist-performed ultrasound for parathyroid disease; in any case, experience and motivation are key.²⁷ In addition to high sensitivity (72%-87% in the reoperative setting), ultrasound has the added advantage of revealing nodular thyroid disease, regional anatomic features, including lymphadenopathy, and postoperative changes from the previous parathyroid exploration, all things that can impact on a subsequent exploration.²⁸ If ultrasound findings are concordant with other available first-time imaging studies, then ultrasound localization may be sufficient to enable parathyroid reoperation. However, cross-sectional imaging will usually be desired. To substantiate ultrasound findings if a parathyroid adenoma candidate is identified, ultrasound-guided fine-needle aspiration for PTH washout can be considered.^{29,30} Ultrasound-guided PTH is not routinely recommended for first-time parathyroid

localization; however, it may be helpful after failed prior parathyroid exploration because of the increased risks of reoperative surgery. If ultrasound scans are nonlocalizing, or if ultrasound findings are equivocal, more imaging studies are indicated.³¹

2.7.2 | Scintigraphy

Ultrasound scans and parathyroid scintigraphy have been shown to play complementary roles; in fact, utilizing both modalities are superior to either imaging method alone.³² Technetium-99m radiolabeled methoxyisobutylisonitrile (known as “MIBI”) is the current standard internationally. Early (about 20-30 minutes) and delayed (2-3 hours) postinjection (dual phase) static planar images are acquired in the typical anterior and oblique views.³³ Although the radiotracer “washes out” from normal tissues, it is persistently accumulated in a parathyroid adenoma.³⁴ In addition to planar images, single photon emission CT (SPECT) and or hybrid SPECT/CT can be performed. The SPECT in addition to planar imaging increases sensitivity to 67%, as compared to 42% for planar imaging alone.³⁵ Further hybrid SPECT/CT offers the combination of functional and anatomic imaging to localize a parathyroid adenoma with a sensitivity approaching 97%.³⁶ In all cases, images should extend below the aortic arch to evaluate for an ectopic parathyroid.

2.7.3 | CT and MRI

The most useful technique – described as 4D CT – involves an initial unenhanced study followed by 2 or 3 contrast-enhanced acquisitions during arterial and venous phases of contrast medium enhancement through the neck and mediastinum.³⁷ The typical parathyroid gland demonstrates peak enhancement on the arterial phase, followed by a washout of contrast on the delayed phase images, thus helping to differentiate it.³⁸⁻⁴⁰ This modality has been shown to be considerably better than both ultrasound and MIBI in localizing parathyroid disease in patients with recurrent or persistent disease after previous surgery.⁴¹⁻⁴³

Dynamic contrast-enhanced MRI may also be used to localize parathyroid adenomas, taking advantage of the hypervascular nature and differential contrast washout from parathyroid adenomas compared with lymph nodes and thyroid tissue.⁴⁴⁻⁴⁶

2.8 | Parathyroid venous sampling and parathyroid angiography

Venous sampling may consist simply of a single sample taken from each internal jugular vein under ultrasound guidance to lateralize disease to one side of the neck or 20 to 30 samples obtained from numerous vessels draining the neck

and upper thorax via a femoral venous approach under fluoroscopic guidance. The latter more invasive procedure should only be considered when other cross-sectional imaging studies and scintigraphy are unhelpful.⁴⁷⁻⁵⁰ Combining venous sampling with selective parathyroid arteriography has been shown to improve localization when compared to venous sampling alone.⁵⁰ Its major advantages are the ability to identify parathyroid glands that cannot be otherwise visualized and to demonstrate venous drainage from neck and upper thoracic vessels that may have been disturbed as a consequence of previous central neck surgery. This study is highly reliant on operator expertise and is potentially associated with serious but uncommon complications, including stroke.

3 | SECTION 2: SURGICAL MANAGEMENT

3.1 | Recommendation 6

Reoperative parathyroid surgery should be performed in the setting of an identified target gland(s) on preoperative imaging studies. Level of evidence: 3A-B, level of recommendation: strong.

The need for a precision operation is imperative in reoperative parathyroid surgery; therefore, having a specific imaged target is essential.⁵¹ Focused exploration and excision based on a preoperative image in conjunction with intraoperative PTH is the most effective way to manage the patient who requires reoperative parathyroid surgery. Unguided bilateral exploration of what can be a significantly scarred central neck is not recommended because it is challenging, often results in a second failure to treat hyperparathyroidism, and risks complications, such as hypoparathyroidism, bilateral vocal cord paralysis, as well as tracheal and cervical esophageal injury.

3.2 | Recommendation 7

Parathyroid reoperations are challenging and should be undertaken by experienced surgeons. Level of evidence: 1-3, level of recommendation: moderate.

National datasets revealed lower cure rates with reoperative parathyroid surgery 84% compared to 95% for first time surgery. Although cure rates are lower, complication rates are higher with a 6-fold increase in vocal cord paralysis and a doubling of bleeding rate compared to primary surgery.⁵² Permanent hypoparathyroidism rates of between 10% and 20% are also described.¹²

Patients should be assessed and managed on a risk benefit basis. Not all patients with recurrent HPT are surgical candidates. Deciding when to operate is complex and multifaceted, balancing a decrease in cure rate with increased complications compared to primary surgery. Discussion by a multidisciplinary team constitutes good clinical practice.

Morbidity, mortality, length of stay, and cost are inversely proportional to surgical volume.^{53–55} Institutional experience has been shown to influence operative success; with higher volume institutions having more favorable outcomes.^{56,57} For primary HPT surgeons, having an annual volume in excess of 50 cases have better outcomes compared with lower volume surgeons but there are no studies examining this question for reoperative surgery.⁵⁸

3.3 | Recommendation 8

Parathyroids should be approached through nondissected planes avoiding, when possible, most heavily scarred regions. Level of evidence: 1-3, level of recommendation: moderate.

In some cases, the patient has cervical scarring from prior thyroid or anterior cervical spine surgery, whereas others have had prior parathyroid surgery. If the first operation is done by an inexperienced parathyroid surgeon who missed a well localized adenoma, reoperation can be rather straightforward because the surgeon failed to go deep enough in the neck for a superior adenoma or inferior enough within the thymus for an inferior parathyroid adenoma.^{59–61}

A number of approaches are available to the reoperative parathyroid surgeon through less-dissected planes, which can make reoperation more likely to be successful and, at the same time, limiting the risks of complications.

3.3.1 | Original midline approach

If a patient has undergone a previous minimally invasive or targeted parathyroidectomy on one side and additional glands are localized on the contralateral side, it is perfectly reasonable to go through an original midline approach, especially if the strap muscles on the side in question have not been badly scarred.^{62,63} If after dealing with an abnormal gland(s) on the previously unoperated side, the intraoperative PTH level does not fall appropriately, then it may be best to approach the original side by a lateral dissection (between straps and sternocleidomastoid) to avoid bleeding from peeling the scarred strap muscles off the thyroid.⁶⁴

3.3.2 | Lateral approach

The lateral approach is ideal for missed superior parathyroid glands in patients who have previously undergone a standard midline approach (see Figure 2).⁶⁵ One of the most commonly missed parathyroid adenomas is the superior adenoma posterior to the recurrent laryngeal nerve within the tracheoesophageal groove or retroesophageal region. With this approach, a plane is developed between the sternocleidomastoid and the strap muscles on the side in question. The contents of the carotid sheath are then retracted laterally, thus exposing the prevertebral fascia and the tracheoesophageal groove. Typically, the




FIGURE 2 The lateral approach. From Thompson GB. “No frills” image-guided exploration. *Op Tech Gen Surg* 1999;1(1):34–48. Used with permission of Mayo Foundation for Medical Education and Research, all rights reserved.

previously undisturbed recurrent laryngeal nerve (RLN) can be easily identified via this approach in a previously undissected plane. The lateral approach may be more difficult after prior low anterior cervical spine surgery as its plane of dissection is similar; however, this alone should not contraindicate the lateral approach.

3.3.3 | Superior approach

If preoperative localization identifies an undescended inferior parathyroid gland at the level of the carotid bifurcation, an ultrasound scan can be utilized to determine the most direct route to this missing gland (see Figure 3).⁶⁵ A small incision can be made in a skin crease directly overlying the gland, and, using a focused approach through previously nondissected planes, the adenoma can be easily identified and removed. Care must be taken to avoid injury to the nearby vagus, superior laryngeal, and hypoglossal nerves.

3.3.4 | Inferior approach

An inferior adenoma within the upper portion of the thymus and/or superior mediastinum can be approached through a




FIGURE 3 The superior approach. From Thompson GB. “No frills” image-guided exploration. *Op Tech Gen Surg* 1999;1(1):34–48. Used with permission of Mayo Foundation for Medical Education and Research, all rights reserved.

previously nondissected plane once the original incision is reopened (see Figure 4).⁶⁵ There is no need to mobilize the thyroid gland on either side. The lower thyroid pole can be exposed, along with the thyrothymic ligament. The thyrothymic ligament can then be separated from the inferior pole and gently retracted upward, often exposing the missed inferior parathyroid adenoma. A map of typical locations for parathyroid discovered at reoperation is presented in Figure 5.⁸

3.4 | Recommendation 9

Intraoperative adjuncts, such as neural monitoring and PTH assay, should be used during reoperative parathyroid surgery. Radioguidance, visible tracers, or ultrasound can be used based on surgeon experience and availability. Level of evidence: 3, level of recommendation: moderate.

3.4.1 | Intraoperative nerve monitoring

There is consensus supporting the routine use of neural monitoring during complex and reoperative thyroid and parathyroid surgery.^{20,66–68} Intraoperative nerve monitoring can be very valuable in reoperative parathyroid surgery, particularly when the missed gland is within a heavily scarred area. With neural monitoring, the vagus can be positively stimulated in the carotid sheath then the RLN can be electrically mapped through the scarred paratracheal region as in a reoperative central neck dissection for recurrent thyroid cancer. Turning up the stimulus intensity to 2 mA can help localize the nerve if scarring prevents direct visualization.⁶⁹ Once the nerve is localized, turning the stimulus intensity back to about 1 mA will reduce false-positive stimulation of surrounding structures. The RLN is generally posterior and deep to inferior parathyroid glands and anterior and superficial to superior glands, excising the latter putting the nerve at greater risk of injury during reoperative parathyroid surgery.^{67,70}

3.4.2 | Intraoperative parathyroid hormone monitoring

When the surgery is directed at preoperatively localized glands, PTH confirmation of success is very accurate.^{61–63} Intraoperative PTH (IOPHT) assay is recommended in reoperative parathyroidectomy to confirm successful excision of hyperfunctioning tissue, with a >50% drop from baseline and into the normal range being the standard.^{8,11,71} This approach can assist in the confirmation of a biochemical cure while avoiding the risks associated with prolonged and unnecessary exploration.




FIGURE 4 A, The inferior approach, initial view of inferior thyroid lobes. B, The thyrothymic ligament is retracted superiorly to deliver the parathyroid adenoma. From Thompson GB. “No frills” image-guided exploration. *Op Tech Gen Surg* 1999;1(1):34–48. Used with permission of Mayo Foundation for Medical Education and Research, all rights reserved.




FIGURE 5 Location of ectopic parathyroid glands found on reoperation. Used with permission of Mayo Foundation for Medical Education and Research, all rights reserved.

3.4.3 | Radioguidance

Radioguidance can be helpful in MIBI-positive single gland persistent or recurrent disease. If this approach is adopted, the *ex vivo* examination of parathyroid tissue, which is hyperfunctional, should exceed 20% of a patient background measurement.^{72,73}

3.5 | Recommendation 10

During reoperative parathyroid surgery when postoperative hypoparathyroidism is a concern, primary autotransplantation should be considered after frozen section biopsy confirmation. Parathyroid cryopreservation can also be considered if available. Level of evidence: 3-5, level of recommendation: moderate.

There are no data to support the use of IOPTH as a determinant in deciding when to autotransplant. Primary (immediate) autotransplantation should be undertaken with caution owing to the possibility of supernumerary gland(s) in reoperative parathyroid cases.^{74,75} This should be optimally reserved for circumstances when it is known that 3 normal glands have previously been excised.⁷⁶

Parathyroid cryopreservation is the process of freezing and storage of parathyroid tissue with a view to later autotransplantation. It is used when it is envisaged that there may be a need to restore or improve parathyroid function in patients rendered hypoparathyroid after parathyroid surgery. At reoperative surgery, the role for cryopreservation/secondary autotransplantation is controversial owing to the limited success rates for survival of auto grafts (30%-50%).^{8,12} The

European consensus statement proposes judicious autograft use.^{21,22} There is a view that cryopreservation should be restricted to centers that have a large experience in this technique owing to a high failure graft rate (up to 90%).^{74,77-79}

4 | SECTION 3: ALTERNATIVES TO REOPERATIVE SURGERY

4.1 | Recommendation 11

Nutritional and pharmacologic optimization should be performed in patients refusing or are not candidates for reoperative parathyroid surgery. Treatable metabolic abnormalities should also be addressed in operative patients. Level of evidence: 1-5, level of recommendation: strong.

There are situations in which the patient who was an initial candidate for parathyroid surgery is no longer suitable in the context of recurrent or persistent parathyroid disease. In these situations, medical approaches can be considered as an alternative to surgery.

4.1.1 | Nutritional

Nutritional guidelines include sufficient intake of calcium and vitamin D. Calcium intake should adhere to the Institute of Medicine guidelines for adults without parathyroid disease.⁸⁰ Intake of between 1000 and 1200 mg from all sources is recommended. The advice to ensure adequate calcium intake is based on the concern that diets low in calcium could conceivably stimulate parathyroids to secrete additional parathyroid hormone.⁸¹

Vitamin D sufficiency is important because vitamin D deficiency in primary hyperparathyroidism is associated with greater manifestations of biochemical abnormalities and target organ compromise.⁸²⁻⁸⁵ Because vitamin D deficiency is associated with more severe manifestations of hyperparathyroidism, it seems prudent to aim for levels >30 ng/mL.¹ In

TABLE 1 A summary of complications of reoperative compared to primary surgery for hyperparathyroidism and key guidance recommendations (British Association of Endocrine and Thyroid Surgeons Audit, 2012)

	First-time PTX	Reoperative PTX
Vocal cord palsy	0.8%	5%
Bleeding	0.5%	1.25%
Recommendation for neural monitoring	No recommendation	Yes
Recommendation for IOPTH	No recommendation	Yes

Abbreviations: IOPTH, intraoperative parathyroid hormone; PTX, parathyroidectomy.

patients who are vitamin D deficient, cautious replacement with judicious amounts of cholecalciferol (vitamin D3) starting with 1000 IU/day is wise.

4.1.2 | Pharmacological

In patients whose hypercalcemia is within 1 mg/dL above the upper limits of normal, most experts would not recommend any specific measures to reduce the serum calcium⁸⁶ because mild hypercalcemia is virtually never associated with symptoms. In patients whose serum calcium is above this threshold, reduction of the serum calcium is a reasonable goal. The few studies with the selective estrogen receptor modulator, raloxifene, have shown modest reductions in the serum calcium.^{87,88} More impressively, the calcimimetic agent, cinacalcet, has been shown in several clinical trials to reduce the serum calcium promptly and persistently.^{89–91} Cinacalcet increases the sensitivity of the calcium-sensing receptor to extracellular calcium. Although cinacalcet is very effective in reducing the serum calcium, circulating levels of PTH fall only modestly. Higher amounts of cinacalcet (>30 mg q.d. or b.i.d.) can be used but gastrointestinal and central nervous system systems can be limiting.

In patients with reduced bone mineral density, cinacalcet is not of benefit because studies extending over 5 years have not shown beneficial bone density changes, despite reductions in the serum calcium.⁹¹ Studies with the bisphosphonate, alendronate, have shown that it increases bone mineral density of the lumbar spine within a year of administration, with further increases seen during the second year.⁹² However, bone density of the hip and distal one-third of the radius is not appreciably changed by alendronate in primary hyperparathyroidism.

In patients who present with both high levels of the serum calcium and reduced bone mineral density that need attention, there have been a few studies using cinacalcet and alendronate together. Dual therapy leads to reductions in the serum calcium and increases in the bone mineral density.^{93,94}

The situation in patients who have had kidney stones and are not candidates for parathyroid surgery is particularly difficult. The etiology of kidney stones, even in those with hypercalciuria, is likely to be multifactorial.³ The use of thiazide diuretics is problematic because serum calcium levels could rise even higher and should be avoided.

ORCID

Brendan C. Stack Jr MD  <http://orcid.org/0000-0003-2896-1615>

REFERENCES

- [1] Hedbäck G, Odén A. Persistent disease after surgery for primary hyperparathyroidism: the long-term outcome. *Eur J Endocrinol*. 2004;150(1):19-25.
- [2] Hinson AM, Stack BC Jr. Evidence-based medicine: approach and references classification. *Medical and Surgical Treatment of Parathyroid Diseases - An Evidence-Based Approach*. Stack BC Jr, Bodenner DL, eds. Cham, Switzerland, Springer Nature Publishing, 2017;2:11-13.
- [3] Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. *J Clin Endocrinol Metab*. 2014;99(10):3561-3569.
- [4] Eastell R, Brandi ML, Costa AG, D'Amour P, Shoback DM, Thakker RV. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. *J Clin Endocrinol Metab*. 2014;99(10):3570-3579.
- [5] Akerström G, Rudberg C, Grimelius L, Johansson H, Lundström B, Rastad J. Causes of failed primary exploration and technical aspects of re-operation in primary hyperparathyroidism. *World J Surg*. 1992;16(4):562-568; discussion 568-569.
- [6] Shen W, Düran M, Morita E, et al. Reoperation for persistent or recurrent primary hyperparathyroidism. *Arch Surg*. 1996;131(8):861-867; discussion 867-869.
- [7] Hindíe E, Zanotti-Fregonara P, Tabarin A, et al. The role of radionuclide imaging in the surgical management of primary hyperparathyroidism. *J Nucl Med*. 2015;56(5):737-744.
- [8] Thompson GB, Grant CS, Perrier ND, et al. Reoperative parathyroid surgery in the era of sestamibi scanning and intraoperative parathyroid hormone monitoring. *Arch Surg*. 1999;134(7):699-704; discussion 704-705.
- [9] Blaine J, Chonchol M, Levi M. Renal control of calcium, phosphate, and magnesium homeostasis. *Clin J Am Soc Nephrol*. 2015;10(7):1257-1272.
- [10] Mark J, Steward D. Reoperative parathyroid surgery, in medical and surgical treatment of parathyroid diseases - an evidence-based approach. *Medical and Surgical Treatment of Parathyroid Diseases - An Evidence-Based Approach*. Stack BC Jr, Bodenner DL, eds. Cham, Switzerland, Springer Nature Publishing, 2017;24:271-280.
- [11] Yen TW, Wang TS, Doffek KM, Krzywda EA, Wilson SD. Reoperative parathyroidectomy: an algorithm for imaging and monitoring of intraoperative parathyroid hormone levels that results in a successful focused approach. *Surgery*. 2008;144(4):611-619; discussion 619-621.
- [12] Bartsch DK, Rothmund M. Reoperative surgery for primary hyperparathyroidism. *Br J Surg*. 2009;96(7):699-701.
- [13] Shin JJ, Milas M, Mitchell J, Berber E, Ross L, Siperstein A. Impact of localization studies and clinical scenario in patients with hyperparathyroidism being evaluated for reoperative neck surgery. *Arch Surg*. 2011;146(12):1397-1403.
- [14] Varoquaux A, Kebebew E, Sebag F, et al. Endocrine tumors associated with the vagus nerve. *Endocr Relat Cancer*. 2016;23(9):R371-R379.
- [15] Duke WS, Vernon HM, Terris DJ. Reoperative parathyroidectomy: overly descended superior adenoma. *Otolaryngol Head Neck Surg*. 2016;154(2):268-271.

- [16] McIntyre CJ, Allen JL, Constantinides VA, Jackson JE, Tolley NS, Palazzo FF. Patterns of disease in patients at a tertiary referral centre requiring reoperative parathyroidectomy. *Ann R Coll Surg Engl*. 2015;97(8):598-602.
- [17] Goodman A, Politz D, Lopez J, Norman J. Intrathyroid parathyroid adenoma: incidence and location—the case against thyroid lobectomy. *Otolaryngol Head Neck Surg*. 2011;144(6):867-871.
- [18] Lappas D, Noussios G, Anagnostis P, Adamidou F, Chatzigeorgiou A, Skandalakis P. Location, number and morphology of parathyroid glands: results from a large anatomical series. *Anat Sci Int*. 2012;87(3):160-164.
- [19] Wilhelm SM, Wang TS, Ruan DT, et al. The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism. *JAMA Surg*. 2016;151(10):959-968.
- [20] Scharpf J, Tuttle M, Wong R, et al. Comprehensive management of recurrent thyroid cancer: an American Head and Neck Society consensus statement: AHNS consensus statement. *Head Neck*. 2016;38(12):1862-1869.
- [21] Bergenfelz A, Salem AF, Jacobsson H, Nordenström E, Almqvist M; Steering Committee for the Scandinavian Quality Register for Thyroid, Parathyroid and Adrenal Surgery (SQRTPA). Risk of recurrent laryngeal nerve palsy in patients undergoing thyroidectomy with and without intraoperative nerve monitoring. *Br J Surg*. 2016;103(13):1828-1838.
- [22] British Association of Endocrine and Thyroid Surgeons (2014). 4th National Audit Report. <http://www.baets.org.uk/wp-content/uploads/2013/05/4th-National-Audit.pdf>. Accessed June 17, 2017.
- [23] Sinclair CF, Bumpous JM, Haugen BR, et al. Laryngeal examination in thyroid and parathyroid surgery: an American Head and Neck Society consensus statement: AHNS Consensus Statement. *Head Neck*. 2016;38(6):811-819.
- [24] Jannasch O, Voigt C, Reschke K, Lippert H, Mroczkowski P. Comparison of outcome between older and younger patients following surgery for primary hyperparathyroidism. *Pol Przegl Chir*. 2013;85(10):598-604.
- [25] Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid*. 2016; 26(1):1-133.
- [26] Chandrasekhar SS, Randolph GW, Seidman MD, et al. Clinical practice guideline: improving voice outcomes after thyroid surgery. *Otolaryngol Head Neck Surg*. 2013;148(6 Suppl):S1-S37.
- [27] Schenk WG III, Hanks JB, Smith PW. Surgeon-performed ultrasound for primary hyperparathyroidism. *Am Surg*. 2013;79(7): 681-685.
- [28] Ghaheri BA, Koslin DB, Wood AH, Cohen JI. Preoperative ultrasound is worthwhile for reoperative parathyroid surgery. *Laryngoscope*. 2004;114(12):2168-2171.
- [29] Kuzu F, Arpacı D, Cakmak GK, et al. Focused parathyroidectomy without intra-operative parathormone monitoring: the value of PTH assay in preoperative ultrasound guided fine needle aspiration washout. *Ann Med Surg (Lond)*. 2016;6:64-67.
- [30] Bancos I, Grant CS, Nadeem S, et al. Risks and benefits of parathyroid fine-needle aspiration with parathyroid hormone washout. *Endocr Pract*. 2012;18(4):441-449.
- [31] Barczynski M, Konturek A, Hubalewska-Dydejczyk A, Cichon S, Nowak W. Utility of intraoperative bilateral internal jugular venous sampling with rapid parathyroid hormone testing in guiding patients with a negative sestamibi scan for minimally invasive parathyroidectomy – a randomized controlled trial. *Langenbecks Arch Surg*. 2009;394(5):827-835.
- [32] Balon HR, Silberstein EB, Meier DA, et al. Society of nuclear medicine procedure guideline for thyroid scintigraphy. Thyroid Scintigraphy version 3.0. 2006. http://interactive.snm.org/docs/Thyroid_Scintigraphy_V3.pdf. Accessed June 17, 2017.
- [33] Greenspan BS, Dillehay G, Intenzo C, et al. SNM practice guideline for parathyroid scintigraphy 4.0. *J Nucl Med Technol*. 2012;40(2):111-118.
- [34] O'Doherty MJ, Kettle AG, Wells P, Collins RE, Coakley AJ. Parathyroid imaging with technetium-99m-sestamibi: preoperative localization and tissue uptake studies. *J Nucl Med*. 1992;33(3):313-318.
- [35] Thomas DL, Bartel TB, Menda Y, Howe J, Graham MM, Juweid ME. Single photon emission computed tomography (SPECT) should be routinely performed for the detection of parathyroid abnormalities utilizing technetium-99m sestamibi parathyroid scintigraphy. *Clin Nucl Med*. 2009;34(10):651-655.
- [36] Bural GG, Muthukrishnan A, Oborski MJ, Mountz JM. Improved benefit of SPECT/CT compared to SPECT alone for the accurate localization of endocrine and neuroendocrine tumors. *Mol Imaging Radionucl Ther*. 2012;21(3):91-96.
- [37] Rodgers SE, Hunter GJ, Hamberg LM, et al. Improved preoperative planning for directed parathyroidectomy with 4-dimensional computed tomography. *Surgery*. 2006;140(6):932-940; discussion 940-941.
- [38] Gafton AR, Glastonbury CM, Eastwood JD, Hoang JK. Parathyroid lesions: characterization with dual-phase arterial and venous enhanced CT of the neck. *AJNR Am J Neuroradiol*. 2012;33(5): 949-952.
- [39] Beland MD, Mayo-Smith WW, Grand DJ, Machan JT, Monchik JM. Dynamic MDCT for localization of occult parathyroid adenomas in 26 patients with primary hyperparathyroidism. *AJR Am J Roentgenol*. 2011;196(1):61-65.
- [40] Rameau A, Eng S, Vu J, Saket R, Jun P, Friduss M. Four-dimensional computed tomography scan utility in parathyroidectomy for primary hyperparathyroidism with low baseline intact parathyroid hormone. *Laryngoscope*. 2017;127(6):1476-1482.
- [41] Hinson AM, Lee DR, Hobbs BA, Fitzgerald RT, Bodenner DL, Stack BC Jr. Preoperative 4D CT localization of nonlocalizing parathyroid adenomas by ultrasound and SPECT-CT. *Otolaryngol Head Neck Surg*. 2015;153(5):775-778.
- [42] Cham S, Sepahdari AR, Hall KE, Yeh MW, Harari A. Dynamic parathyroid computed tomography (4DCT) facilitates reoperative parathyroidectomy and enables cure of missed hyperplasia. *Ann Surg Oncol*. 2015;22(11):3537-3542.
- [43] Mortenson MM, Evans DB, Lee JE, et al. Parathyroid exploration in the reoperative neck: improved preoperative localization with 4D-computed tomography. *J Am Coll Surg*. 2008;206(5): 888-895; discussion 895-896.

- [44] Nael K, Hur J, Bauer A, et al. Dynamic 4D MRI for characterization of parathyroid adenomas: multiparametric analysis. *AJNR Am J Neuroradiol*. 2015;36(11):2147-2152.
- [45] Kluijfhout WP, Venkatesh S, Beninato T, et al. Performance of magnetic resonance imaging in the evaluation of first-time and reoperative primary hyperparathyroidism. *Surgery*. 2016;160(3):747-754.
- [46] Merchavy S, Luckman J, Guindy M, Segev Y, Khafif A. 4D MRI for the localization of parathyroid adenoma: a novel method in evolution. *Otolaryngol Head Neck Surg*. 2016;154(3):446-448.
- [47] Lebastchi AH, Aruny JE, Donovan PI, et al. Real-time super selective venous sampling in remedial parathyroid surgery. *J Am Coll Surg*. 2015;220(6):994-1000.
- [48] Reidel MA, Schilling T, Graf S, et al. Localization of hyperfunctioning parathyroid glands by selective venous sampling in reoperation for primary or secondary hyperparathyroidism. *Surgery*. 2006;140:907-913; discussion 913.
- [49] Sugg SL, Fraker DL, Alexander R, et al. Prospective evaluation of selective venous sampling for parathyroid hormone concentration in patients undergoing reoperations for primary hyperparathyroidism. *Surgery*. 1993;114(6):1004-1009; discussion 1009-1010.
- [50] Miller DL, Doppman JL, Krudy AG, et al. Localization of parathyroid adenomas in patients who have undergone surgery. Part II. Invasive procedures. *Radiology*. 1987;162(1 Pt 1):138-141.
- [51] Fraker DL, Harsono H, Lewis R. Minimally invasive parathyroidectomy: benefits and requirements of localization, diagnosis, and intraoperative PTH monitoring. Long-term results. *World J Surg*. 2009;33(11):2256-2265.
- [52] The British Association of Endocrine & Thyroid Surgeons. Fourth National Audit Report October 2012. <http://www.baets.org.uk/wp-content/uploads/2013/05/4th-National-Audit.pdf>. ISBN 978-0-9568154-3-9. Accessed June 17, 2017.
- [53] Thielmann A, Kerr P. Validation of selective use of intraoperative PTH monitoring in parathyroidectomy. *J Otolaryngol Head Neck Surg*. 2017;46(1):10.
- [54] Sosa JA, Powe NR, Levine MA, Udelsman R, Zeiger MA. Profile of a clinical practice: thresholds for surgery and surgical outcomes for patients with primary hyperparathyroidism: a national survey of endocrine surgeons. *J Clin Endocrinol Metab*. 1998;83(8):2658-2665.
- [55] Stavarakis AI, Ituarte PH, Ko CY, Yeh MW. Surgeon volume as a predictor of outcomes in inpatient and outpatient endocrine surgery. *Surgery*. 2007;142(6):887-899; discussion 887-899.
- [56] Mitchell J, Milas M, Barbosa G, Sutton J, Berber E, Siperstein A. Avoidable reoperations for thyroid and parathyroid surgery: effect of hospital volume. *Surgery*. 2008;144(6):899-906; discussion 906-907.
- [57] Chen H, Wang TS, Yen TW, et al. Operative failures after parathyroidectomy for hyperparathyroidism: the influence of surgical volume. *Ann Surg*. 2010;252(4):691-695.
- [58] Zarebczan B, Chen H. Influence of surgical volume on operative failures for hyperparathyroidism. *Adv Surg*. 2011;45:237-248.
- [59] Caron NR, Sturgeon C, Clark OH. Persistent and recurrent hyperparathyroidism. *Curr Treat Options Oncol*. 2004;5(4):335-345.
- [60] Hessman O, Stålberg P, Sundin A, et al. High success rate of parathyroid reoperation may be achieved with improved localization diagnosis. *World J Surg*. 2008;32(5):774-781; discussion 782-783.
- [61] Parikh PP, Farra JC, Allan BJ, Lew JI. Long-term effectiveness of localization studies and intraoperative parathormone monitoring in patients undergoing reoperative parathyroidectomy for persistent or recurrent hyperparathyroidism. *Am J Surg*. 2015; 210(1):117-122.
- [62] Richards ML, Thompson GB, Farley DR, Grant CS. Reoperative parathyroidectomy in 228 patients during the era of minimal-access surgery and intraoperative parathyroid hormone monitoring. *Am J Surg*. 2008;916(6):937-942; discussion 972-973.
- [63] Udelsman R. Approach to the patient with persistent or recurrent primary hyperparathyroidism. *J Clin Endocrinol Metab*. 2011;96(10):2950-2958.
- [64] Simental A, Ferris RL. Reoperative parathyroidectomy. *Otolaryngol Clin North Am*. 2008;41(6):1269-1274.
- [65] Thompson GB. "No frills" image-guided exploration. *Oper Tech Gen Surg*. 1999;1(1):34-48.
- [66] Shindo ML, Caruana SM, Kandil E, et al. Management of invasive well-differentiated thyroid cancer: an American Head and Neck Society consensus statement. AHNS consensus statement. *Head Neck*. 2014;36(10):1379-1390.
- [67] Scharpf J, Randolph GW. Nerve monitoring in parathyroid surgery, in medical and surgical treatment of parathyroid diseases - an evidence-based approach. *Medical and Surgical Treatment of Parathyroid Diseases - An Evidence-Based Approach*. Stack BC Jr, Bodenner DL, eds. Cham, Switzerland, Springer Nature Publishing, 2017;36:459-468.
- [68] Bergenfelz AO, Hellman P, Harrison B, Sitges-Serra A, Dralle H; European Society of Endocrine Surgeons. Positional statement of the European Society of Endocrine Surgeons (ESES) on modern techniques in pHPT surgery. *Langenbecks Arch Surg*. 2009;394(5):761-764.
- [69] Randolph GW, Kamani D. Intraoperative electrophysiologic monitoring of the recurrent laryngeal nerve during thyroid and parathyroid surgery: experience with 1,381 nerves at risk. *Laryngoscope*. 2017;127(1):280-286.
- [70] Yarbrough DE, Thompson GB, Kasperbauer JL, Harper CM, Grant CS. Intraoperative electromyographic monitoring of the recurrent laryngeal nerve in reoperative thyroid and parathyroid surgery. *Surgery*. 2004;136(6):1107-1115.
- [71] Sun PY, Thompson SM, Andrews JC, et al. Selective parathyroid hormone venous sampling in patients with persistent or recurrent primary hyperparathyroidism and negative, equivocal or discordant noninvasive imaging. *World J Surg*. 2016;40(12):2956-2963.
- [72] Cox MD, Stack BC Jr. Minimally invasive radioguided parathyroidectomy, in medical and surgical treatment of parathyroid diseases - an evidence-based approach. *Medical and Surgical Treatment of Parathyroid Diseases - An Evidence-Based Approach*. Stack BC Jr, Bodenner DL, eds. Cham, Switzerland, Springer Nature Publishing, 2017;17:181-202.
- [73] Candell L, Campbell MJ, Shen WT, Gosnell JE, Clark OH, Duh QY. Ultrasound-guided methylene blue dye injection for

- parathyroid localization in the reoperative neck. *World J Surg.* 2014;38(1):88-91.
- [74] Borot S, Lapierre V, Carnaille B, Goudet P, Penfornis A. Results of cryopreserved parathyroid autografts: a retrospective multicenter study. *Surgery.* 2010;147(4):529-535.
- [75] Mihai R, Barczynski M, Iacobone M, Sitges-Serra A. Surgical strategy for sporadic primary hyperparathyroidism: an evidence-based approach to surgical strategy, patient selection, surgical access, and reoperations. *Langenbecks Arch Surg.* 2009;394(5):785-798.
- [76] Henry JF. Reoperation for primary hyperparathyroidism: tips and tricks. *Langenbecks Arch Surg.* 2010;395(2):103-109.
- [77] Shepet K, Alhefthi A, Usedom R, Sippel R, Chen H. Parathyroid cryopreservation after parathyroidectomy: a worthwhile practice? *Ann Surg Oncol.* 2013;20(7):2256-2260.
- [78] Marcucci G, Della Pepa G, Brandi ML. Natpara for the treatment of hypoparathyroidism. *Expert Opin Biol Ther.* 2016;16(11):1417-1424.
- [79] Stack BC Jr, Bimston DN, Bodenner DL, et al. American Association of Clinical Endocrinologists and American College of Endocrinology disease state clinical review: postoperative hypoparathyroidism—definitions and management. *Endocr Pract.* 2015;21(6):674-685.
- [80] Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. *J Clin Endocrinol Metab.* 2011;96(1):53-58.
- [81] Jorde R, Szumlas K, Haug E, Sundsfjord J. The effects of calcium supplementation to patients with primary hyperparathyroidism and a low calcium intake. *Eur J Nutr.* 2002;41(6):258-263.
- [82] Mithal A, Bandeira F, Meng X, et al. Primary hyperparathyroidism in India, Brazil and China. In: *The Parathyroids, 2nd Edition.* Bilezikian JP, Marcus R, Levine MA, eds. Academic Press, San Diego, CA, 2001:375-386.
- [83] Walker MD, Cong E, Lee JA, et al. Low vitamin D levels have become less common in primary hyperparathyroidism. *Osteoporos Int.* 2015;26(12):2837-2843.
- [84] Vieth R. Why the minimum desirable serum 25-hydroxyvitamin D level should be 75 nmol/L (30 ng/ml). *Best Pract Res Clin Endocrinol Metab.* 2011;25(4):681-691.
- [85] Rolighed L, Rejnmark L, Sikjaer T, et al. Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial. *J Clin Endocrinol Metab.* 2014;99(3):1072-1080.
- [86] Marcocci C, Bollerslev J, Khan AA, Shoback DM. Medical management of primary hyperparathyroidism: proceedings of the fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism. *J Clin Endocrinol Metab.* 2014;99(10):3607-3618.
- [87] Marcus R, Madvig P, Crim M, Pont A, Kosek J. Conjugated estrogens in the treatment of postmenopausal women with hyperparathyroidism. *Ann Intern Med.* 1984;100(5):633-640.
- [88] Rubin MR, Lee KH, McMahon DJ, Silverberg SJ. Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. *J Clin Endocrinol Metab.* 2003;88(3):1174-1178.
- [89] Peacock M, Bolognese MA, Borofsky M, et al. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. *J Clin Endocrinol Metab.* 2009;94(12):4860-4867.
- [90] Iglesias P, Ais G, Gonzalez A, et al. Acute and one-year effects of cinacalcet in patients with persistent primary hyperparathyroidism after unsuccessful parathyroidectomy. *Am J Med Sci.* 2008;335(2):111-114.
- [91] Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback DM. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. *J Clin Endocrinol Metab.* 2005;90(1):135-141.
- [92] Silverberg SJ, Rubin MR, Faiman C, et al. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. *J Clin Endocrinol Metab.* 2007;92(10):3803-3808.
- [93] Khan AA, Bilezikian JP, Kung AW, et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. *J Clin Endocrinol Metab.* 2004;89(7):3319-3325.
- [94] Faggiano A, Di Somma C, Ramundo V, et al. Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism. *Endocrine.* 2011;39(3):283-287.

How to cite this article: Stack BC, Tolley NS, Bartel TB, et al. AHNS Series: Do you know your guidelines? Optimizing outcomes in reoperative parathyroid surgery: Definitive multidisciplinary joint consensus guidelines of the American Head and Neck Society and the British Association of Endocrine and Thyroid Surgeons. *Head & Neck.* 2018;40:1617–1629. <https://doi.org/10.1002/hed.25023>